CAMELOT BIOMEDICAL SYSTEMS SRL

Their core work

Camelot Biomedical Systems is a Genova-based SME that develops computational algorithms and software for biomedical imaging and medical robotics applications. Their work bridges advanced mathematics — including optimization, spectral methods, and machine learning — with practical clinical tools such as 3D reconstruction for minimally invasive surgery. As a private company participating in MSCA training networks, they serve as an industry host providing real-world R&D environments where early-stage researchers apply mathematical methods to biomedical problems. Their technical core lies at the intersection of data-driven optimization and medical image processing.

What they specialise in

How they've shifted over time

Camelot's early H2020 involvement (2018) centered on foundational mathematical methods — nonlocal operators, spectral decomposition on graphs, and general-purpose data science and machine learning for biomedical imaging. By 2019-2020, their focus shifted decisively toward applied clinical problems: autonomous surgical navigation, active catheter systems, and large-scale optimization for image processing pipelines. The trajectory shows a company moving from abstract computational research toward deployment-ready algorithms for specific medical procedures.

Camelot is moving from general-purpose computational methods toward algorithm development for autonomous medical devices and clinical decision support, making them increasingly relevant for medtech and surgical robotics consortia.

How they like to work

Camelot has never coordinated an H2020 project, consistently joining as a participant or third party — typical of a specialist SME that contributes domain-specific technical capability rather than managing large consortia. With 50 unique partners across 13 countries from just 3 projects, they operate within large MSCA training networks and are comfortable in multi-partner, multi-national environments. Their role pattern suggests they are sought after as an industry placement partner who grounds academic research in applied biomedical problems.

Despite only 3 projects, Camelot has built a broad network of 50 partners across 13 countries, a direct result of participating in large MSCA training networks that typically involve 10-15+ organizations each. Their network spans much of Europe but is rooted in Italy's biomedical technology ecosystem.

What sets them apart

Camelot occupies a niche as a private company that bridges pure mathematics and clinical medicine — they translate optimization theory and spectral methods into working biomedical software, which is rare among SMEs. Their participation in MSCA networks as an industry host means they attract and train researchers who can move between mathematical rigor and medical application. For consortium builders, they offer something hard to find: a company small enough to be hands-on, but mathematically sophisticated enough to collaborate directly with university research groups on algorithm development.

Highlights from their portfolio

• TraDE-OPT
  Their largest funded project (EUR 261,500), focused on training researchers in data-driven optimization — signals their core commercial interest in scalable algorithm development.
• ATLAS
  Autonomous intraluminal surgery is a high-impact clinical application combining robotics, imaging, and navigation — represents Camelot's push into applied medical device territory.
• NoMADS
  Foundational project connecting nonlocal mathematical methods to biomedical imaging and point cloud processing — reveals the theoretical depth behind their applied work.